Sarepta Therapeutics, Inc.

LSE:0L35 Stock Report

Market Cap: US$12.2b

Sarepta Therapeutics Management

Management criteria checks 4/4

Sarepta Therapeutics' CEO is Doug Ingram, appointed in Jun 2017, has a tenure of 6.83 years. total yearly compensation is $1.66M, comprised of 48.1% salary and 51.9% bonuses, including company stock and options. directly owns 0.41% of the company’s shares, worth $50.26M. The average tenure of the management team and the board of directors is 3.3 years and 7.9 years respectively.

Key information

Doug Ingram

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage48.1%
CEO tenure6.8yrs
CEO ownership0.4%
Management average tenure3.3yrs
Board average tenure7.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Doug Ingram's remuneration changed compared to Sarepta Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$800k

-US$536m

Sep 30 2023n/an/a

-US$691m

Jun 30 2023n/an/a

-US$908m

Mar 31 2023n/an/a

-US$1b

Dec 31 2022US$125mUS$740k

-US$703m

Sep 30 2022n/an/a

-US$716m

Jun 30 2022n/an/a

-US$507m

Mar 31 2022n/an/a

-US$357m

Dec 31 2021US$2mUS$730k

-US$419m

Sep 30 2021n/an/a

-US$486m

Jun 30 2021n/an/a

-US$634m

Mar 31 2021n/an/a

-US$704m

Dec 31 2020US$1mUS$669k

-US$554m

Sep 30 2020n/an/a

-US$601m

Jun 30 2020n/an/a

-US$530m

Mar 31 2020n/an/a

-US$656m

Dec 31 2019US$1mUS$650k

-US$715m

Sep 30 2019n/an/a

-US$620m

Jun 30 2019n/an/a

-US$570m

Mar 31 2019n/an/a

-US$403m

Dec 31 2018US$1mUS$650k

-US$362m

Sep 30 2018n/an/a

-US$245m

Jun 30 2018n/an/a

-US$216m

Mar 31 2018n/an/a

-US$170m

Dec 31 2017US$57mUS$338k

-US$51m

Compensation vs Market: Doug's total compensation ($USD1.66M) is below average for companies of similar size in the UK market ($USD5.62M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.

CEO

Doug Ingram (60 yo)

6.8yrs

Tenure

US$1,661,338

Compensation

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...

Leadership Team

NamePositionTenureCompensationOwnership
Douglas Ingram
President6.8yrsUS$1.66m0.41%
$ 50.3m
Ian Estepan
Executive VP & CFO3.3yrsUS$3.71m0.038%
$ 4.7m
Bilal Arif
Executive VP & Chief Technical Operations Officer1.3yrsUS$3.52m0.027%
$ 3.2m
Louise Rodino-Klapac
Executive VP3.3yrsUS$3.72m0.072%
$ 8.8m
Ryan Brown
Executive VP3.3yrsUS$3.58m0.030%
$ 3.7m
Francesca Nolan
Executive Director of Investor Relations and Corporate Communicationsno datano datano data
Alison Nasisi
Executive VP & Chief People Officer2.5yrsno datano data
Diane Berry
Executive VP and Chief of Global Policy & Advocacy Officer4.6yrsno datano data
Dallan Murray
Executive VP & Chief Customer Officer3.3yrsno datano data
Will Tilton
Senior VP1.3yrsno datano data
Joseph Bratica
Controller & VP7.1yrsUS$911.89kno data
Mary Jenkins
Senior Manager of Investor Relationsno datano datano data

3.3yrs

Average Tenure

49yo

Average Age

Experienced Management: 0L35's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Douglas Ingram
President6.8yrsUS$1.66m0.41%
$ 50.3m
M. Behrens
Independent Chairwoman15.1yrsUS$594.99k0.19%
$ 23.6m
Hans Wigzell
Chairman of Corporate Strategy Board & Independent Non-Employee Director13.8yrsUS$546.99k0.022%
$ 2.7m
Richard Barry
Independent Director8.8yrsUS$563.65k3.36%
$ 409.3m
Beverly Davidson
Member of Strategic & Scientific Advisory Board8.7yrsno datano data
Joy Cavagnaro
Member of Scientific Advisory Board4.4yrsno datano data
Louis Kunkel
Member of Strategic & Scientific Advisory Board8.7yrsno datano data
Claude Nicaise
Independent Non-Employee Director8.8yrsUS$553.34k0.016%
$ 1.9m
Kenneth Fischbeck
Member of Strategic & Scientific Advisory Board7.1yrsno datano data
Carsten Bonnemann
Member of Scientific Advisory Board4.3yrsno datano data
Matthew Wood
Member of Strategic & Scientific Advisory Board7.1yrsno datano data
Annemieke Aartsma-Rus
Member of Scientific Advisory Board4.4yrsno datano data

7.9yrs

Average Tenure

70yo

Average Age

Experienced Board: 0L35's board of directors are considered experienced (7.9 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.